참고문헌
- Yeh, E.T, Tong, AT, Lenihan, (2009) Cardiovascular complications of cancer therapy; diagnosis, pathogenesis, and management. J Am Coll Cardiol. Jun 16; 2231-2247. https://doi.org/10.1016/j.jacc.2009.02.050
- Floyd, Nguyen, Lobins, (2005) Cardiotoxicity of cancer therapy; Journal Clin Oncol 23:7685. https://doi.org/10.1200/JCO.2005.08.789
- Singal, Iliskovic, PK (1998) Doxorubicin induced cardiomyopathy; NEJM 339:900-905. https://doi.org/10.1056/NEJM199809243391307
- Singal, PK, Deally, CMR, Weinberg,(1987) Subcellular effects of adriamycin in the heart: A concise review. J Mol Cell Cardiol 19:817. https://doi.org/10.1016/S0022-2828(87)80392-9
- Von Hoff, DD, Rozencweig, M, Layard, M, (1977) Daunomycin-induced cardiotoxicity in children and adults. Am J Med 62:220
- Seifert, CF, Nesser, ME, Thompson, (1994) Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother 28:1063. https://doi.org/10.1177/106002809402800912
- Sehested M, (1994) Dexrazoxane for Protection Against Cardiotoxic Effects of Anthracyclines, J Clin Oncol, 14:2884.
- Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuos infusion. Ann Intern Med. 96: 133-9. https://doi.org/10.7326/0003-4819-96-2-133
- Schuchter LM, Hensley ML, Meropol, (2002) 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology, J Clin Oncol, 20:2895-2903. https://doi.org/10.1200/JCO.2002.04.178
- Chiron BV. In (1995) Cardioxane Product Monograph. Amsterdan, The Netherlands.
- Bu'Lock FA, Gabriel HM, Oakhill A (1993), Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J. Aug;70(2):185-188. https://doi.org/10.1136/hrt.70.2.185
- Steven E. Lipshultz SE, Rifai N, Dalton VM, (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. NEJM. Jul 8:145-153. https://doi.org/10.1056/NEJMoa035153
-
Marty M, Espié M, Llombart A (2006) multicenter randomized phase III study of the cardioprotective effect of dexrazoxane(
$cardioxane^{(R)}$ ) in advanced/metastastic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology 17:614-622 https://doi.org/10.1093/annonc/mdj134 - Ranulfo Pinheiro de Matos Neto RP, Petrilli AS, (2006). Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. Arq Bras Cardiol. Dec; 87:763-771. https://doi.org/10.1590/S0066-782X2006001900013
- Moghrabi A, Levy DE, Asselin B, (2007). Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. Feb 1;109:896-904.
- Lipshultz SE, Sanders SP, Goorin AM (1994) Monitoring for anthracycline cardiotoxicity. Pediatrics:433-437.
- Lipshultz SE, Sanders SP, Goorin AM, (1994) The anthracycline cardiotoxicity debate. Pediatrics 94;781-782.
- Haycock GB, Schwartz GJ, Wisotsky DH, (1978) Geometric method for measuring body surface area: A height-weight formula validated in infants, children and adults. J Pediatr 93;62-66. https://doi.org/10.1016/S0022-3476(78)80601-5